Short answer
GYRE THERAPEUTICS, INC. (GYRE) filed an 8-K current report with the SEC on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Press release covers financial results for the three and nine months ended September 30, 2026.
GYRE THERAPEUTICS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Press release covers financial results for the three and nine months ended September 30, 2026
- Investor-relevant figures and management commentary are contained in Exhibit 99.1
- Results provide the latest update on Gyre’s operating performance and financial position
Item 7.01 · Regulation FD Disclosure
- Updated corporate presentation released November 5, 2026, signaling refreshed investor messaging
- Exhibit 99.2 contains the substantive presentation, potentially including business, pipeline or strategy updates
Item EX-99.1 · Exhibit EX-99.1
- Q3 revenue $32.9M, up 1%; ETUARY sales $31.4M offset lower Etorel and Contiva revenue under China procurement
- Q3 net loss $2.5M, versus $1.9M income; basic EPS $(0.04), reflecting higher operating and other expenses
- Nine-month net loss $35.3M, versus $4.6M income; revenue fell $6.5M to $86.5M after Astellas collaboration revenue ended
- Cash and investments $98.8M, down 15% from December 31, 2025; liquidity supports pipeline execution but burn remains material
- F351 NMPA decision expected by year-end 2026 or Q1 2027; full-year revenue guidance $100.5M to $111.0M affirmed
Item EX-99.2 · Exhibit EX-99.2
- Corporate presentation frames China operations and ETUARY revenue as funding for a diversified U.S.-China degrader pipeline
- ETUARY FY26 revenue guidance $100.5M-$111M, supporting capital-efficient research without dilution dependence
- F351 Phase 3 fibrosis regression 52.85% versus placebo 29.84%, with NMPA decision expected by YE26/1Q27
- F351 potential China launch in 1H27, adding a near-term growth catalyst to the commercial fibrosis portfolio
- CG001419 Phase 1 completed, with Phase 2 cancer-induced bone pain study planned in the U.S. or China
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other GYRE THERAPEUTICS, INC. 8-K filings
Get the next GYRE 8-K as it lands
Follow GYRE for push alerts, or ask the research agent what this filing means.